

Initial Submission Ibrance (Capsules 75 mg)

Reg No. 1C 68/60 (NC)

Approval date 26 Sep 2017

Variation submission

Application number	Scope	Approval date	Product Information affected	Summary
15005/63 (N)	<b>MaV-2</b> : Change of content of product labeling	3 Mar 2020	SmPC , PIL	
15063/62(N)	non-AVG	12 Jul 2019		
15058/62 (N)	<b>MiV-PA 2</b> Change of product labeling (in accordance to country specific labeling requirement)	27 May 2019	Patient information leaflet	
15081/61 (N)	<b>MaV-15</b> Extension of shelf-life of the drug product	14 Feb 2019		
15011/61 (N)	<b>MaV1</b> Change and/or additional indication/dosing regimen/patient population/inclusion of clinical information extending the usage of the product	5 Oct 2018	Patient information leaflet	
15021/61 (N)	<b>MiV-PA 30</b> Change of pack size/fill volume and/or change of shape or dimension of container or closure for non-sterile product	1 Oct 2018		
15062/61 (N)	<b>MiV-PA 2</b> Change of product labeling (in accordance to country specific labeling requirement)	19 Jan 2018	Patient information leaflet	

